ARBITER-2: judging the next step in lipid management

Statin therapy is established as the basis of lipid-lowering
therapy in all patients with established atherosclerotic
disease.1 However, statin trials show that 50–70% of
cardiovascular events cannot be prevented by statins alone.2,3
This raises the question about the next step that should be
taken to prevent further events in high-risk patients already
on a statin.ITED